Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
{{output}}
ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In additio... ...
